CGBio Launches Spray-Type Skin Protection Medical Device "Easyef MD Spray"

Incorporating DW-EGF Developed by Daewoong Pharmaceutical
and a Nano-Clay Based Formulation

CGBio, a company specializing in regenerative medicine, announced the launch of its spray-type skin protection medical device, 'Easyef MD Spray'.

Easyef MD Spray is a spray-type skin protection medical device that incorporates 'DW-EGF', a highly active epidermal growth factor developed by Daewoong Pharmaceutical, and a nano-clay based formulation. This product is designed to be sprayed onto areas such as the oral mucosa and surgical wounds. After application, it forms a physical protective barrier that adheres closely to the skin and mucous membranes, shielding the wound area from external irritation and contaminants. It can also help maintain an optimal moist environment at the wound site.

Spray-type skin protective medical device 'Easyef MD Spray'. CGBio

Recently, there has been growing interest in non-contact wound protection solutions that enhance both procedural convenience for medical professionals and ease of use for patients, in response to the increasing frequency of outpatient treatments and the expanding demand for at-home care. In particular, there is a rising need for formulations that are easy and reliable to use on sensitive areas or regions where direct contact is undesirable, such as after surgical procedures or on the oral mucosa.

Easyef MD Spray was developed to meet these needs. By utilizing a spray type, it minimizes direct contact and allows for easy application to wide or hard-to-reach areas. Additionally, the nano-clay based viscous formulation enables the formation of a stable protective barrier that adheres securely to the area of application.

Notably, Easyef MD Spray can be used not only on the skin but also on the oral mucosa, expanding its range of applications. Since the oral mucosa and surgical wound areas are easily exposed to external irritation and contamination, Easyef MD Spray can physically protect these sites and help maintain an appropriate moist environment.

The DW-EGF incorporated in this product is a highly active epidermal growth factor based on Korea's first biopharmaceutical technology, developed by Daewoong Pharmaceutical. With the same structure as human EGF, it is utilized in the fields of skin and wound care.

Easyef MD Spray can also be stored at room temperature, enhancing storage convenience in healthcare settings such as hospitals and clinics. Its portability and ease of use make it suitable for a variety of clinical environments.

Through the launch of this product, CGBio plans to expand its portfolio of wound care and skin protection solutions, and to transfer its accumulated expertise in biomaterial technology from bone and tissue regeneration into the wound care sector. The company aims to grow its market presence based on distribution centered around hospitals and clinics.

Hyunseung Yoo, CEO of CGBio, stated, "Easyef MD Spray is a spray-type skin protection medical device that combines DW-EGF with nano-clay technology to deliver both ease of use and wound protection. As a product applicable to a range of areas, including surgical wounds and the oral mucosa, we will continue to offer differentiated solutions in the fields of wound care and regenerative medicine going forward."

This content was produced with the assistance of AI translation services.